Synapse

← JHEP Reports

Papers in JHEP Reports

Page 14 · newest first

  1. Tumour cell-expressed PD-L1 reprograms lipid metabolism via EGFR/ITGB4/SREBP1c signalling in liver cancerJHEP Reports · 2024
  2. Long-term open-label vebicorvir for chronic HBV infection: Safety and off-treatment responsesThe Medicine Forum · 2024
  3. Primary liver cancer classification from routine tumour biopsy using weakly supervised deep learningJHEP Reports · 2024
  4. Impact of age on NIS2+™ and other non-invasive blood tests for the evaluation of liver disease and detection of at-risk MASHJHEP Reports · 2024
  5. Universal screening for HCV infection in China: An effectiveness and cost-effectiveness analysisJHEP Reports · 2024
  6. Microbiota modulation by dietary oat beta-glucan prevents steatotic liver disease progressionJHEP Reports · 2024
  7. Dynamic evolution of the sofosbuvir-associated variant A1343V in HEV-infected patients under concomitant sofosbuvir-ribavirin treatmentJHEP Reports · 2024
  8. Intrapancreatic fat deposition is unrelated to liver steatosis in metabolic dysfunction-associated steatotic liver diseaseJHEP Reports · 2024
  9. Introducing adjuvant-loaded particulate hepatitis B core antigen as an alternative therapeutic hepatitis B vaccine componentJHEP Reports · 2023
  10. Predictive value of platelet-to-lymphocyte and neutrophil-to-lymphocyte ratio in HCC treated with sorafenib and radioembolizationJHEP Reports · 2023
  11. Concurrent nivolumab and external beam radiation therapy for hepatocellular carcinoma with macrovascular invasion: A phase II studyJHEP Reports · 2023
  12. AlcoChange: A digital therapeutic for patients with alcohol-related liver diseaseJHEP Reports · 2023
  13. Cognitive dysfunction in early experimental metabolic dysfunction-associated steatotic liver disease is associated with systemic inflammation and neuroinflammationJHEP Reports · 2023
  14. Whole blood RNA sequencing identifies transcriptional differences between primary sclerosing cholangitis and ulcerative colitisJHEP Reports · 2023
  15. Expert opinion on bleeding risk from invasive procedures in cirrhosisJHEP Reports · 2023
  16. Cholangiocarcinoma across England: Temporal changes in incidence, survival and routes to diagnosis by region and level of socioeconomic deprivationJHEP Reports · 2023
  17. Odevixibat treatment in an adult patient with advanced icteric progressive cholestatic liver diseaseJHEP Reports · 2023
  18. A meta-analysis and real-world cohort study on the sex-related differences in efficacy and safety of immunotherapy for hepatocellular carcinomaJHEP Reports · 2023
  19. Prevention of lipid droplet accumulation by DGAT1 inhibition ameliorates sepsis-induced liver injury and inflammationJHEP Reports · 2023
  20. 90Y-/166Ho- ‘Radiation lobectomy’ for liver tumors induces abnormal morphology and impaired drainage of peritumor lymphaticsJHEP Reports · 2023
  21. Association of HBsAg levels with differential gene expression in NK, CD8 T, and memory B cells in treated patients with chronic HBVJHEP Reports · 2023
  22. Evolution of spontaneous portosystemic shunts over time and following aetiological intervention in patients with cirrhosisJHEP Reports · 2023
  23. Rates, patterns, and predictors of specialty palliative care consultation among patients with acute-on-chronic liver failureJHEP Reports · 2023
  24. Safety, pharmacodynamics, and antiviral activity of selgantolimod in viremic patients with chronic hepatitis B virus infectionJHEP Reports · 2023
  25. AKR1B1 drives hyperglycemia-induced metabolic reprogramming in MASLD-associated hepatocellular carcinomaJHEP Reports · 2023
  26. Ultra-processed food consumption and non-alcoholic fatty liver disease, metabolic syndrome and insulin resistance: A systematic reviewJHEP Reports · 2023
  27. Efferocytosis in liver diseaseJHEP Reports · 2023
  28. Transplant oncology – Current indications and strategies to advance the fieldJHEP Reports · 2023
  29. Modelling HDV kinetics under the entry inhibitor bulevirtide suggests the existence of two HDV-infected cell populationsJHEP Reports · 2023
  30. Myosteatosis: Diagnosis, pathophysiology and consequences in metabolic dysfunction-associated steatotic liver diseaseJHEP Reports · 2023
  31. Roles of innate lymphoid cells in metabolic and alcohol-associated liver diseasesJHEP Reports · 2023
  32. Adenosine A2a receptor inhibition increases the anti-tumor efficacy of anti-PD1 treatment in murine hepatobiliary cancersJHEP Reports · 2023
  33. Radiological diagnosis of hepatocellular carcinoma does not preclude biopsy before treatmentJHEP Reports · 2023
  34. Heterogeneity in intrahepatic macrophage populations and druggable target expression in patients with steatotic liver disease-related fibrosisJHEP Reports · 2023
  35. Hospital frailty risk score is superior to legacy comorbidity indices for risk adjustment of in-hospital cirrhosis casesJHEP Reports · 2023
  36. Ketamine restriction correlates with reduced cholestatic liver injury and improved outcomes in critically ill patients with burn injuryJHEP Reports · 2023
  37. Low sphingolipid levels predict poor survival in patients with alcohol-related liver diseaseJHEP Reports · 2023
  38. Lower free triiodothyronine (fT3) levels in cirrhosis are linked to systemic inflammation, higher risk of acute-on-chronic liver failure, and mortalityJHEP Reports · 2023
  39. Spleen stiffness measurement predicts decompensation and rules out high-risk oesophageal varices in primary biliary cholangitisJHEP Reports · 2023
  40. Maternal liver-related symptoms during pregnancy in primary sclerosing cholangitisJHEP Reports · 2023
  41. Opinion paper on the diagnosis and treatment of progressive familial intrahepatic cholestasisJHEP Reports · 2023
  42. Time-of-day-dependent variation of the human liver transcriptome and metabolome is disrupted in MASLDJHEP Reports · 2023
  43. Expert management of congenital portosystemic shunts and their complicationsJHEP Reports · 2023
  44. Liver transplant selection criteria and outcomes in critically ill patients with ACLFJHEP Reports · 2023
  45. Critical shortfalls in the management of PBC: Results of a UK-wide, population-based evaluation of care deliveryJHEP Reports · 2023
  46. Development and optimisation of a reception testing protocol designed to eliminate HCV in the UK prison populationJHEP Reports · 2023
  47. SARS-CoV-2 receptor ACE2 is upregulated by fatty acids in human MASHJHEP Reports · 2023
  48. Pharmacological activation of constitutive androstane receptor induces female-specific modulation of hepatic metabolismJHEP Reports · 2023
  49. Transient elastography and von Willebrand factor as predictors of portal hypertension and decompensation in childrenJHEP Reports · 2023
  50. Platelet adhesion assessed by PFA-100 is not linked to progression of ACLDJHEP Reports · 2023